Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oteseconazole for prevention of recurrent vulvovaginal candidiasis in Japanese women
jRCT2080224624Phase 3Completed
- Sponsor
- Mycovia Pharmaceuticals
- Start
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in recurrent vulvovaginal candidiasis (RVVC) comparing Oteseconazole with Placebo (2 arms). Primary endpoint: Proportion of subjects with ≥1 acute VVC episode during maintenance phase (ITT population). Started Apr 2019; status: completed.
02
Drugs
oteseconazole
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on jRCT2080224624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224624.